Stereotaxis
STXS
About: Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems; Disposables, Royalty; and Sublease, of which a majority of revenue is generated from the Disposables, service, and accessories stream.
Employees: 139
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
151% more call options, than puts
Call options by funds: $118K | Put options by funds: $47K
24% more capital invested
Capital invested by funds: $69.4M [Q1] → $86.1M (+$16.7M) [Q2]
1.34% more ownership
Funds ownership: 45.88% [Q1] → 47.22% (+1.34%) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 3 [Q1] → 3 (+0) [Q2]
7% less repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 28
2% less funds holding
Funds holding: 86 [Q1] → 84 (-2) [Q2]
13% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 8
Financial journalist opinion
Based on 4 articles about STXS published over the past 30 days
